+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID06917001

Randomized Double-Blind Trial Testing Safety and Initial Effectiveness of Oral Resomelagon for Adults With Dengue Infection

Led by Federal University of Minas Gerais · Updated on 2026-09-15

120

Participants Needed

2

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Resomelagon as a potential treatment for adults with Dengue virus infection. This randomized, double-blind, placebo-controlled Phase 2a trial aims to understand if Resomelagon is safe to use in dengue patients and whether it can reduce the duration of illness. The study is based on prior research showing anti-inflammatory and pro-resolving effects of Resomelagon in animal models and COVID-19 patients, suggesting it may help decrease disease severity and inflammatory responses in dengue. Participants will be randomly assigned to receive either Resomelagon 100mg orally once daily plus standard treatment or a placebo plus standard treatment. The standard treatment includes hydration and symptomatic therapy as needed for dengue fever. The study is designed to compare these groups over the treatment period to evaluate safety and efficacy. During the trial, participants will take the assigned medication and undergo blood tests to monitor their health and response. Researchers will assess safety over 28 days and measure how Resomelagon affects the duration and severity of illness, plasma leakage, and hospitalization rates within 10 days. The study includes careful monitoring of clinical and laboratory criteria to evaluate outcomes, with the entire participation lasting up to about a month.

CONDITIONS

Brief Title

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

Research Team

P

Pedro RJ Almeida, MD MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here